CAR T-cell therapy in pediatric oncology: From leukemia to emerging promise in Wilms tumor and solid malignancies
Author / Expert
Mustafa Azizoglu, Asli Pinar Zorba Yildiz, Ibrahim Baytar, Gonca Gercel, Ayten Ceren Bakir, Toni Risteski, Tuba Erdem Sit, Fatima Berre Yaman, Maria Escolino, Ciro Esposito
Topic overview
CAR T cell therapy represents an advanced immunotherapeutic modality in pediatric oncology, involving genetic modification of a patient's own T cells to recognize and destroy cancer cells, offering highly targeted and personalized treatment. Originating from immunotherapy research in the 1980s, first-generation CARs were developed in 1989–1993, followed by second-generation CARs in the early 2000s with enhanced efficacy. FDA approval led to its first pediatric use in 2013, achieving complete remission in a child with acute lymphoblastic leukemia (ALL) [1–3].
Comments